PROTACs based on VHL ligand targeting coronavirus 3CL protease and preparation method and application thereof
The invention discloses PROTACs based on VHL ligand targeted coronavirus 3CL protease as well as a preparation method and application thereof, and belongs to the field of medicinal chemistry. The compound or a tautomer, a mesomer, a raceme, an enantiomer, a non-corresponding isomer, a hydrate or a p...
Gespeichert in:
Hauptverfasser: | , , , , , , , , , , , , , , , , , , , |
---|---|
Format: | Patent |
Sprache: | chi ; eng |
Schlagworte: | |
Online-Zugang: | Volltext bestellen |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | The invention discloses PROTACs based on VHL ligand targeted coronavirus 3CL protease as well as a preparation method and application thereof, and belongs to the field of medicinal chemistry. The compound or a tautomer, a mesomer, a raceme, an enantiomer, a non-corresponding isomer, a hydrate or a pharmaceutically acceptable salt thereof has a structure as shown in a formula I or a formula II. Ligand (S, R, S)-AHPC of VHL is selected as a part combined with E3 ligase in PROTACs, a coronavirus 3CL protease inhibitor is a small molecule compound of targeted target protein, and the two parts are connected by selecting a proper connecting chain to construct the PROTACs. The coronavirus 3CL protease inhibitor overcomes the defects that an existing coronavirus 3CL protease inhibitor is single in structure type, limited in pharmacodynamic approach (only having an inhibition effect) and the like, has good inhibition and degradation activity on coronavirus 3CL protease, and can be used as an anti-coronavirus drug for |
---|